Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer

摘要: Quietly, cautiously, and steadily, the field of modern medicine recently progressed across a new threshold with development Rexin-G, first so far, only, targeted injectable molecular genetic to be validated in clinic. Designed function within context complexities human circulatory system, “smart,” “stealth,” “highly-selective” nanoparticles embodied Rexin-G travel beyond reach most gifted surgeons, horizons finest catheters, seek out biochemical hallmarks invasive cancers, deliver lethal payload where it is needed most—i.e., targeting histopathology tumor microenvironment. In this invited review, we elaborate upon critical stages scientific discovery, molecular-genetic target validation, preclinical studies, pathotropic (disease-seeking) platform development, clinical trial design, pharmacology, regulatory considerations, GMP production & bioprocessing that, taken together, define advancement tumor-targeted for cancer. course delineating developmental trajectory into series logical discrete stages, authors have endeavored extract, abstract, represent host biotechnological innovations an accessible manner, providing (i) useful overview converging fields applied genetics, nanotechnology, biotechnology, (ii) conceptual basis advancing pipeline products emerging medicine.